A phase 2 trial of extended induction epratuzumab and rituximab for previously untreated follicular lymphoma: CALGB 50701 Academic Article uri icon

Overview

MeSH Major

  • Antibodies, Monoclonal, Humanized
  • Antibodies, Monoclonal, Murine-Derived
  • Immunotherapy
  • Lymphoma, Follicular

abstract

  • The high response rate and prolonged time to progression observed with this antibody combination are comparable to those observed after standard chemoimmunotherapies and further support the development of biologic, nonchemotherapeutic approaches for these patients.

publication date

  • November 2013

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC3828050

Digital Object Identifier (DOI)

  • 10.1002/cncr.28299

PubMed ID

  • 23922187

Additional Document Info

start page

  • 3797

end page

  • 804

volume

  • 119

number

  • 21